Similar articles

• Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

  Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Dancey JE, et al. Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215558
• Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

  Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Ivy SP, et al. Clin Cancer Res. 2010 Mar 15;16(6):1726-36. doi: 10.1158/1078-0432.CCR-09-1961. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215542 Free PMC article.
• [Monitoring of clinical trials and interim analysis. 1. Monitoring committee].

  Boutitie F, Bellissant E, Blanchard J, Boissel JP, Cauquil J, Chauvin F, Derzko G, Ducruet T, Durrleman S, Girre JP, et al. Boutitie F, et al. Therapie. 1992 Jul-Aug;47(4):345-9. Therapie. 1992. PMID: 1494799 Review. French.
• ["Workshop on Data Monitoring Committee in NIH"--data monitoring in cancer clinical trial].

  Sakamoto J, Nakazato H. Sakamoto J, et al. Gan To Kagaku Ryoho. 1992 Jul;19(7):1099-104. Gan To Kagaku Ryoho. 1992. PMID: 1626947 Japanese. No abstract available.
• United States military contributions to the National Cancer Institute.

  Sarvis JA, Thompson IM. Sarvis JA, et al. Urol Oncol. 2009 Sep-Oct;27(5):558-61. doi: 10.1016/j.urolonc.2009.01.025. Urol Oncol. 2009. PMID: 19720303 Review.